22 related articles for article (PubMed ID: 11164739)
1. Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities.
Lam P; Cheung F; Tan HY; Wang N; Yuen MF; Feng Y
Int J Mol Sci; 2016 Mar; 17(4):465. PubMed ID: 27043533
[TBL] [Abstract][Full Text] [Related]
2. Does herbal medicine reduce the risk of hepatocellular carcinoma?
Rino Y; Yukawa N; Yamamoto N
World J Gastroenterol; 2015 Oct; 21(37):10598-603. PubMed ID: 26457019
[TBL] [Abstract][Full Text] [Related]
3. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
4. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
5. [Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B].
Liu P; Hu YY; Liu C; Xu LM; Liu CH; Sun KW; Hu DC; Yin YK; Zhou XQ; Wan MB; Cai X; Zhang ZQ; Ye J; Tang BZ; He J
Zhong Xi Yi Jie He Xue Bao; 2003 Jul; 1(2):89-98, 102. PubMed ID: 15339577
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
[TBL] [Abstract][Full Text] [Related]
7. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis.
Chao DT; Lim JK; Ayoub WS; Nguyen LH; Nguyen MH
Aliment Pharmacol Ther; 2014 Feb; 39(4):349-58. PubMed ID: 24387289
[TBL] [Abstract][Full Text] [Related]
11. Does the control of alanine aminotransferase levels lead to a regression of liver fibrosis in chronic hepatitis C patients?
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
Hepatol Res; 2001 Feb; 19(2):144-157. PubMed ID: 11164739
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
